(a) Perform a cost-benefit analysis of diabetes screening for this group. Does it favor screening?

Similar documents
Folland et al Chapter 4

Final Exam - section 2. Thursday, December hours, 30 minutes

Sociology 63993, Exam1 February 12, 2015 Richard Williams, University of Notre Dame,

m 11 m.1 > m 12 m.2 risk for smokers risk for nonsmokers

The Economics of Obesity

Write your identification number on each paper and cover sheet (the number stated in the upper right hand corner on your exam cover).

Notes for laboratory session 2

Econometric analysis and counterfactual studies in the context of IA practices

Glossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha

Regression Output: Table 5 (Random Effects OLS) Random-effects GLS regression Number of obs = 1806 Group variable (i): subject Number of groups = 70

Multiple Linear Regression Analysis

Sensitivity, Specificity and Predictive Value [adapted from Altman and Bland BMJ.com]

MODEL I: DRINK REGRESSED ON GPA & MALE, WITHOUT CENTERING

Basic statistics for public health and policy

Cost-effectiveness analysis of a screening programme. Iris Lansdorp-Vogelaar, PhD Department of Public Health Erasmus MC, Rotterdam

A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making

Name: emergency please discuss this with the exam proctor. 6. Vanderbilt s academic honor code applies.

Economic Evaluation. Introduction to Economic Evaluation

Economics 345 Applied Econometrics

MIDTERM EXAM. Total 150. Problem Points Grade. STAT 541 Introduction to Biostatistics. Name. Spring 2008 Ismor Fischer

CAUSAL EFFECT HETEROGENEITY IN OBSERVATIONAL DATA

Age (continuous) Gender (0=Male, 1=Female) SES (1=Low, 2=Medium, 3=High) Prior Victimization (0= Not Victimized, 1=Victimized)

The cost of cancer treatment

Study Guide for the Final Exam

Insurance Guide For Dental Healthcare Professionals

Midterm STAT-UB.0003 Regression and Forecasting Models. I will not lie, cheat or steal to gain an academic advantage, or tolerate those who do.

ADDING VALUE AND EXPERTISE FOR SUCCESSFUL MARKET ACCESS. Per Sørensen, Lundbeck A/S

Nisreen Salti Associate Professor Department of Economics American University of Beirut

Sociology Exam 3 Answer Key [Draft] May 9, 201 3

The Logic of Causal Order Richard Williams, University of Notre Dame, Last revised February 15, 2015

Evidence based assessment of the value of innovation: pricing solutions and prospects

Mark Scheme (Results) Summer Pearson Edexcel GCE AS Level in Economics A (8EC0) Paper 01 Introduction to Markets and Market Failure

NUTRITION & HEALTH YAO PAN

4. STATA output of the analysis

Wednesday October 4, 2017

Type of intervention Other: transplantation. Economic study type Cost-utility analysis.

An Analytical Review of the Pew Report Entitled, It Takes A Team and the Accompanying Productivity and Profit Calculator

THE SECOND REVOLUTION IN HEALTH CARE

Assess the view that a minimum price on alcohol is likely to be an effective and equitable intervention to curb externalities from drinking (25)

INSTRUCTOR S NOTE. Copyright 2018, The Johns Hopkins University and Teaching Vaccine Economics Everywhere.

C-Change Making the Business Case Questions & Answers

Food for thought. Department of Health Services Research 1

Student name: SOCI 420 Advanced Methods of Social Research Fall 2017

Minimum Unit Pricing & Banning Below Cost Selling: Estimated policy impacts in England 2014/15

Chapter 8 notes Human Capital: Education and Health (rough notes, use only as guidance; more details provided in lecture)

Task Force Finding and Rationale Statement

REVIEW PROBLEMS FOR FIRST EXAM

Hepatitis C Treatment for the Poor and Imprisoned: A Call to Action

Health economics for device developers: a framework for assessing commercial viability

Healthy People, Healthy Communities

Back to the future: should we live in a post-qaly world?

Introduction to regression

Student name: SOCI 420 Advanced Methods of Social Research Fall 2017

How to evaluate the economic impact of interventions I: introduction and costing analyses

GPP 501 Microeconomic Analysis for Public Policy Fall 2017

Chapter 3. Producing Data

Announcement. Homework #2 due next Friday at 5pm. Midterm is in 2 weeks. It will cover everything through the end of next week (week 5).

ECON Introductory Econometrics Seminar 7

Centers for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC,

The Economics of Tobacco and Tobacco Taxation in Bangladesh: Abul Barkat et.al

Cost-effectiveness of gastric bypass for severe obesity Craig B M, Tseng D S

Running head: BREAST CANCER SCREENING 1

Jad Chaaban Assistant Professor Department of Agriculture. Nisreen Salti Assistant Professor Department of Economics

Lessons from the LIPGENE Project: Economic Issues in Producing and Supplying Special Lipid- Modified Foods

Tobacco Health Cost in Egypt

ARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY

Tobacco & Poverty. Tobacco Use Makes the Poor Poorer; Tobacco Tax Increases Can Change That. Introduction. Impacts of Tobacco Use on the Poor

economics survey. Results of a mini behavioral

Hospitals could save two millions - if someone acted

How Confident Are Yo u?

Consultation on WHO ART Guidelines

Sampling Uncertainty / Sample Size for Cost-Effectiveness Analysis

Revisiting Barriers to Trade: Do Foregone Health Benefits Matter?

SCREENING FOR ATRIAL FIBRILLATION IN CANADIAN PHARMACIES IS COST-EFFECTIVE

COST-BENEFIT ANALYSIS: underground cabeling of power distribution networks as a climate change adaptation measure

AP Statistics Practice Test Ch. 3 and Previous

Math 261 Exam I Spring Name:

University of Groningen. The Economics of assisted reproduction Connolly, Mark Patrick

NICE DECISION SUPPORT UNIT

THIS PROBLEM HAS BEEN SOLVED BY USING THE CALCULATOR. A 90% CONFIDENCE INTERVAL IS ALSO SHOWN. ALL QUESTIONS ARE LISTED BELOW THE RESULTS.

Chapter 1 Review Questions

Econ C07: Economics of Medical Care. Marginal and Average Productivity

F1: Introduction to Econometrics

Report Information from ProQuest

About the National Centre for Pharmacoeconomics

Cost-Utility Analysis (CUA) Explained

An Overview of Health Economics Data and Expertise in Cancer

STAT 200. Guided Exercise 4

Incentives and payment systems in dentistry. Jostein Grytten Institute of Community Dentistry University of Oslo EADPH, Vilnius, 10 June, 2017

Political Science 15, Winter 2014 Final Review

2015 Survey on Prescription Drugs

Homie Razavi. CDA Foundation Polaris Observatory. From Economic Analysis to Financial Dialogue

The Healthy Indiana Plan

Understanding public and private genetic testing for cancer risk. Frequently asked questions

Opioid Addiction Statistics

Instructions for doing two-sample t-test in Excel

Asia s Diabetes Challenge

Abstract. When one looks at the legalization of marijuana, he can choose many

Insights from 10,000 Women on the Impact of NCDs Executive Summary. Executive Summary

Transcription:

Cameron ECON 132 (Health Economics): SECOND MIDTERM EXAM (A) Winter 18 Answer all questions in the space provided on the exam. Total of 36 points (and worth 22.5% of final grade). Read each question carefully, so that you answer the question. Short Answer (6 points each question) 1. A study in the May 4 2004 issue of the Annals of Internal Medicine considered the costeffectiveness and cost-benefit of screening people with hypertension (blood pressure of 140/90 or higher) for Type 2 Diabetes among people with hypertension. Assume - 5 percent of people with hypertension have undiagnosed diabetes. - Early diagnosis of diabetes saves 0.2 years of life per person with previously undiagnosed diabetes. - A year of life is valued at $100,000. - Early diagnosis of diabetes increases health costs (due to treatment of diabetes for a longer period of time) by $10,000 per person with previously undiagnosed diabetes. We consider the costs and benefits of diabetes screening for 10,000 people with hypertension and with undiagnosed diabetes. In parts (a) and (b) assume that there are no direct costs for the actual screening tests, the only cost is the indirect cost of receiving more health care, and that the screening detects all cases of undiagnosed diabetes. (a) Perform a cost-benefit analysis of diabetes screening for this group. Does it favor screening? (b) What is the cost of screening per life-year saved? (c) Now additionally suppose that there are direct costs for the actual screening tests: - an initial screening test (a capillary blood glucose test) costs $25 per person tested - this picks up 90% of those with undiagnosed diabetes, but also wrongly suggests that 10% of those without diabetes have diabetes. - a confirmatory test (a fasting plasma glucose test) costs $20. This is only given to those diagnosed using the initial screening test and is perfect in detecting who really has diabetes. What is the direct cost of screening 10,000 people?

2.(a) For the following diagram (i) Which of points A to J is society s optimum in the absence of moral hazard? (ii) Which of points A to J is society s optimum in the presence of moral hazard? (b) Suppose all individuals face a loss distribution that is uniformly distributed on ($3,000, $9,000). Each individual knows his loss but the insurance company does not. If all individuals are risk neutral will the insurance company make a profit if it sells a complete-cover insurance policy for $6,000 (and faces administration costs of $1,000 per policy)? Explain your answer. (c)(i) Provide a definition of adverse selection. (ii) Explain what is meant by a health insurance death spiral. 3. Circle True or False to each of the following statements about the U.S. health market. [One point each.] (a) True False Given adverse selection, private health insurance markets cannot provide a standardized policy with the same premium and benefits for everyone. (b) True False The sixth stool Guaiac test article showed that one test was optimal. (c) True False Cost-benefit analysis attempts to replace market demand & supply curves. (d) True False U.S. government agencies place the value of a life at over $5 million. (e) True False The main reason for a gatekeeper is to reduce adverse selection problems. (f) True False A limitation of the difference-in-differences method is that it cannot be used to obtain estimates that can be given a causal interpretation. 2

4.(a) Consider the following tradeoff between health capital (H) and consumption of other goods (Z). Suppose new medical technology leads to improved health outcomes at no additional cost. (i) Show the effect of this change on the above diagram. (ii) For your diagram show whether this change has led to increased or decreased health capital. (b) The World Health Organization (WHO) is considering sending in teams of experts to deal with an outbreak of a disease in a distant country. Sending more teams will prevent more fatalities. It costs $100,000 per team spent and they estimate the following effectiveness: Number of teams Lives saved 1 500 2 600 3 610 4 612 5 613 6 613 Suppose saving a life is valued at $20,000. What is the optimal number of teams? Explain your answer. (c)(i) Provide the definition of a QALY. (ii) Explain the benefit in health settings of using cost-effectiveness analysis rather than costbenefit analysis. 3

5. We have data on medical spending (variable spending) for individuals who are in exactly one of three possible insurance plans. Variable plan1 = 1 if in plan 1 and = 0 otherwise. Variable plan2 = 1 if in plan 2 and = 0 otherwise. Variable plan3 = 1 if in plan 3 and = 0 otherwise.. sum spending plan1 plan2 plan3 Variable Obs Mean Std. Dev. Min Max spending 616 1505.769 2403.662 10.1652 28519.2 plan1 616.3279221.4698378 0 1 plan2 616.5454545.4983343 0 1 plan3 616.1266234.3328208 0 1. regress spending plan1 plan3, vce(robust) Robust spending Coef. Std. Err. t P> t [95% Conf. Interval] plan1-530.4282 202.5152-2.62 0.009-928.136-132.7204 plan3-780.6911 201.3257-3.88 0.000-1176.063-385.3194 _cons 1778.561 155.2871 11.45 0.000 1473.602 2083.521. test plan1 plan3 ( 1) plan1 = 0 ( 2) plan3 = 0 F( 2, 613) = 7.60 Pro b > F = 0.0005 (i) For which plan was medical spending the highest? Explain your answer. (ii) Is the difference in spending across the three plans statistically significant at the 5% level? Explain your answer. If there is not enough information to answer this question then say so. (iii) What is the difference in the average amount of spending in plans 1 and 3? Explain your answer. (iv) Suppose we additionally have a variable income that has data on annual income. Give Stata commands that would enable us to compute the income elasticity of health spending. (v)-(vi) The following table gives the sample mean of variable waz, studied in the Stata exercise in assignment 3. Given these data, give an estimate of the treatment effect. Show computations. Treatment = High Treatment = Low Year==93 0.54 0.44 Year==98 0.32 0.07 4

Multiple Choice (1 point each) Note: You should spend 15-20 % of time on these! 1. Which of the following countries has universal government provided single-payer insurance a. Britain b. Germany c. United States d. Afghanistan 2. Standard health policy methods for estimating the value of a life are a. willingness to pay to avoid risks b. willingness to accept risks c. neither a. nor b. d. both a. and b. 3. The main motivation for the individual mandate component of the original Affordable Care Act was to a. reduce moral hazard b. reduce adverse selection c. improve chance of Republican support in the U.S. Congress 4. We estimate the model y = β 1 + β 2 T + β 3 S + β 4 T S + error, where T=0 pre-treatment and T=1 post-treatment and S=1 if treated and S=0 if not treated, The difference-in-difference estimate of treatment is a. β 2 b. β 3 c. β 4 5. In homework 3 the variable waz measured a. weight b. weight divided by age c. weight at each age standardized to have mean near 0 and variance near 1. 6. The traditional model for consumer demand is adequate for explaining the impact on individual demand for health of a. changes in the prices of health care b. sickness of an individual c. both a. and b. d. neither of the above. 5